Shifting our awareness to the financial fourth quarter of 2022 CADL Deficit has widen at $-0.15 per share, relative to the results of $1.54 per share a year prior quarter, In the prior quarter CADL realized $-0.30 per share.

Candel Therapeutics Inc stock quotes, charts, profile

Candel Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement

In the fourth quarter of 2022 earnings season Invesco Db G10 Currency Harvest Fund reached break-even at $0.00 per share, opposite of $0.00 per share a year prior quarter, In the preceding quarter DBV realized $0.00 per share.

Invesco Db G10 Currency Harvest Fund Customers

Invesco Db G10 Currency Harvest Fund Income Statement, Balance sheets, Cash Flow Statement

Revenues were $5.940523 millions but Topline Up moderately at in the financial period closing December 31 2022

For the financial period closing December 31 2022 company realized net loss per share of $0.00 in contrast to $0.02 a year ago, while Revenues advanced by 4.764 % to $5.94 millions from the corresponding reporting season a year ago.

Galaxy Gaming Inc Customers

Galaxy Gaming Inc Suppliers

The company created positive surprise for the investors, displaying an important gain in fiscal three months ending December 31 2022 with operating loss of $-7.346 millions

The investors haven't expected any moderations at the top-line during the the October to December 31 2022 reporting season at the company. But, shareholders observe CALAs' operating loss which came in at $-7.346 millions, in the same period.

Calithera Biosciences Inc stock quotes, charts, profile

Calithera Biosciences Inc Income Statement, Balance sheets, Cash Flow Statement

Revenues receded in single digits, at Quaint Oak Bancorp Inc amid the fiscal three months closing Dec 31 2022

For the fiscal fourth quarter of 2022 Quaint Oak Bancorp Inc income per share plummeted by -44.5 % of $0.55 per share compare to $0.99 a year ago and profit plummeted by -55.19 % from $1.22 per share from the previous reporting season.

Revenues depreciated by -6.343 % to $8.80 millions from $9.40 millions in the similar reporting season a year ago and sequentially Revenues fell by -26.514 % from $11.98 millions.

Quaint Oak Bancorp Inc Suppliers

Quaint Oak Bancorp Inc Income Statement, Balance sheets, Cash Flow Statement

Facing difficult business enviroment, with rather steep -15.427 %, Revenues decrease, the Socket Mobile Inc amid the fourth quarter of 2022

In the fourth quarter of 2022 financial report Computer Hardware company reported soft top and bottom-line, where reached zero gain and revenue by -15.427 % year on year. Revenue were to $5.17 millions in contrast to $6.11 millions eps at $0.00 compared to $0.09 in the corresponding period a prior year.

Socket Mobile Inc Customers

Socket Mobile Inc Suppliers

Better Therapeutics Inc created some good news for the stock market, presenting a relevant growth in fiscal time-frame closing Dec 31 2022 with operating deficit of $-8.322 millions

The shareholders haven't assumed some moderations at the business during the the earnings season of the October to December 31 2022 time at the Better Therapeutics Inc . However, stockholders monitor the Medical Equipment & Supplies company's operating deficit that has been at $-8.322 millions, during the same period.

Better Therapeutics Inc stock quotes, charts, profile

Better Therapeutics Inc rise Rates, Profitability, PE

For the fiscal fourth quarter of 2022 Aptevo Therapeutics Inc decreased a loss per share of $-0.84 per share compare to $-1.28 a year before and Income per Share improved from $-1.50 per share from the prior quarter.

Revenues remained unaffected to $0.00 millions from $3.67 millions in the same quarter a year before and sequentially Revenues surged from $0.00 millions.

Aptevo Therapeutics Inc Customers

Aptevo Therapeutics Inc growth Rates, Profitability, PE

Shifting our attention to the financial interval closing Dec 31 2022 Candel Therapeutics Inc Losses have extended at $-0.15 per share, relative to the recent numbers of $1.54 per share a year before quarter, In the previous quarter the Biotechnology & Pharmaceuticals company realized $-0.30 per share.

Candel Therapeutics Inc Suppliers

Candel Therapeutics Inc Revenue growth Rates

In the financial period ending December 31 2022 DBV reached zero gain at $0.00 per share, opposite of $0.00 per share a year prior reporting period, In the preceding reporting period The company realized $0.00 per share.

Invesco Db G10 Currency Harvest Fund Suppliers

Invesco Db G10 Currency Harvest Fund Income Statement, Balance sheets, Cash Flow Statement

Revenues have been $5.940523 millions but Topline Up softly at the Galaxy Gaming Inc in the fiscal three months closing Dec 31 2022

For the most recent fiscal period GLXZ realized net deficit per share of $0.00 compared to $0.02 a year before, while Revenues advanced by 4.764 % to $5.94 millions from the similar reporting season a year before.

Galaxy Gaming Inc Suppliers

Galaxy Gaming Inc advance Rates, Profitability, PE

Between many entities, the CALA issued also its fourth quarter of 2022 numbers

The Major Pharmaceutical Preparations sector reporters continue to digest the fourth quarter of 2022 earnings. Today they observe operating loss of $-7.346 millions, from the Calithera Biosciences Inc , which hasn't cited any top-line still, for the respective October to December 31 2022 quarter.

Calithera Biosciences Inc stock quotes, charts, profile

Calithera Biosciences Inc Income Statement, Balance sheets, Cash Flow Statement

Redemption of Deficit at VDI in the fourth quarter of 2022

Respectable Revenue advance in the October to December 31 2022, by 52.984 % to $76.19 millions supported to cut losses to $-1.33 per share, from $-1.79 in corresponding the reporting season a year prior.

Vantage Drilling International stock quotes, charts, profile

Vantage Drilling International advance Rates, Profitability, PE